Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Ignyta, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pfizer, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Community Practice Connections™: 12th Annual New York Lung Cancers Symposium


Release Date: February 28, 2018
Expiration Date: February 28, 2019
Media: Internet - based

 

Activity Overview

Community Practice Connections™: 12th Annual New York Lung Cancer Symposium® features a case-based discussion of current and developing therapies for patients with non–small cell lung cancers (NSCLCs), including immunotherapy and inhibition of EGFR, ALK, and other oncogenic drivers. Interactive clinical vignettes are followed by short video interviews with leading lung cancer experts and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians engaged in the care of patients with NSCLCs.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Ignyta, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pfizer, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

CME/CE Activity Table of Contents

  • Module 1: Immunotherapy in Lung Cancer
  • Module 2: EGFR Mutation-Positive NSCLC
  • Module 3. ALK and Other Oncogenic Drivers

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate. 

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Determine testing strategies to optimize tumor characterization and inform clinical decision making for the management of patients with lung cancers
  • Identify diagnostic and tumor testing results that inform individualized treatment planning and sequencing for patients with non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
  • Integrate recent clinical trial findings concerning single-agent and combination immunotherapeutic strategies to manage advanced forms of lung cancers
  • Apply personalized approaches to optimize sequencing of oncogenic-driven NSCLC via assessment of mutation subtypes in multiple lines of care
  • Determine frontline and subsequent options in patients without actionable mutations, including the role of chemotherapies and antiangiogenic strategies in these settings
  • Describe methods to proactively plan for and mitigate the impact of treatment-related toxicities in the care of patients with lung cancers

Faculty, Staff, and Planners' Disclosures

Faculty

Justin F. Gainor, MD
Assistant Professor
Harvard Medical School
Massachusetts General Hospital
Boston, MA
 

Disclosure: Consultant: Novartis, Bristol-Myers Squibb, Genentech, Theravance, Loxo; Other: Honorarium for speaking engagements from Merck and Incyte.

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosure: Consultant: AstraZeneca

Paul K. Paik, MD
Assistant Attending Physician
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosure: Grant/ Research Support: Celgene, EMD Serono

Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, NY

Disclosure: Grant/Research Support: National Cancer Institute; Consultant: AstraZeneca, Clovis, Roche/Genentech, Boehringer Ingelheim, Lilly, Adgero; Stock/Shareholder: Adgero, Stelexis

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By